Table 5. Patient pharmacokinetic parameters.

	PEG-LD (mg m−2) Cycle 1	Vd (l m−2) Cycle 1	Clearance (ml h−1 m−2) Cycle 1	Terminal half-life (h) Cycle 1	AUC 0 → ∞ (μg h ml−1) Cycle 1
Patient #	Cycle 2	Cycle 2	Cycle 2	Cycle 2	Cycle 2
1	20	1.4	32	44	622
	8	2.3	17	101	492
2	20	0.9	12	63	1693
	16	0.9	13	88	1301
3	20	1.6	25	44	789
	20	1.8	19	65	1041
4	20	1.4	18	55	1115
	20	1.6	17	65	1175
5	20	1.2	17	48	1165
	20	1.2	19	52	1082
6	20	1.0	26	50	784
	22	1.5	3	336	6257
7	22	0.7	38	40	581
	22	1.4	20	48	1090
8	22	1.8	38	43	579
	22	2.0	32	45	690
9	25	2.0	22	63	1122
	25	1.7	12	102	2470
10	25	1.9	29	48	870
	25	1.7	20	60	1299
11	25	2.3	73	34	343
	25	1.4	37	40	684
12	25	1.1	11	73	2279
	25	0.9	11	83	2348
13	25	1.4	29	48	869
	25	1.8	27	55	945
14	25	1.1	10	99	2408
	25	1.1	10	101	2767
Mean Cycle 1		1.4	27	54	1087
CV%		32	60	31	58
Mean Cycle 2		1.5	18	89	1689
CV%		27	49	84	88

PEG-LD=pegylated liposomal doxorubicin.